What does this research mean for the field?

Pml induction reduces ALS symptoms and extends survival in mice with NEK1-linked ALS by promoting degradation of toxic Nek1 proteins. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

This study aims to understand how Pml influences NEK1 degradation and its effects on ALS progression.

March 12, 2026

Pml loss worsens NEK1-linked ALS and Pml induction drives NEK1 degradation, precluding disease onset.

Key Points

This study aims to understand how Pml influences NEK1 degradation and its effects on ALS progression.
Developed mice models with NEK1 mutations to analyze ALS symptoms.
Assessed the effects of Pml ablation and induction on ALS symptoms and protein aggregation.
Utilized poly(I:C) treatment to activate the interferon pathway in vivo.
Pml ablation led to ALS symptoms in heterozygote mice, resembling human conditions.
Induction of Pml significantly reduced NEK1 aggregation and associated symptoms.
Survival of mice improved by 5 months with Pml activation through interferon pathway.

Abstract

Germinal mono-allelic loss-of-function mutations of NEK1 drive amyotrophic lateral sclerosis (ALS) at variable penetrance, presumably through haploinsufficiency. Modeling the ALS-associated Arg812Ter mutation in mice revealed that the resulting truncated Nek1 (Nek1t) is aggregation-prone, particularly in alpha-motoneurons (αMNs), and drives canonical ALS symptoms when bi-allelically expressed (Nek1t/t). Promyelocytic leukemia (Pml) ablation allows for ALS symptoms to occur even in heterozygote Nek1wt/t animals, mimicking the human situation. Pml precludes disease occurrence by promoting SUMO-facilitated degradation of Nek1t proteins through PML nuclear bodies (NBs). Conversely, Pml induction, achieved by activating the interferon pathway via poly(I:C) treatment, clears Nek1t puncta in αMNs, dramatically reducing ALS-associated symptoms and extending survival by 5 months. Our studies highlight the role of mutant NEK1 expression in ALS pathogenesis and identifies activation of interferon pathways as a candidate therapeutic strategy that promotes Pml-triggered SUMOylation/degradation of toxic misfolded proteins in vivo, yielding dramatic clinical improvement. These observations provide strong proof-of-concept support to validate PML as a relevant therapeutic target in neurodegenerative conditions associated with protein misfolding and putative aggregation.

Mark Helpful

Bookmark

Relay